The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01519661




Registration number
NCT01519661
Ethics application status
Date submitted
24/01/2012
Date registered
27/01/2012
Date last updated
10/02/2015

Titles & IDs
Public title
Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Scientific title
A Single Arm, Open-label, Multicenter, Phase IV Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis
Secondary ID [1] 0 0
2011-002000-32
Secondary ID [2] 0 0
CTBM100C2401
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Infections 0 0
Pseudomonas Aeruginosa in Cystic Fibrosis 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Cystic fibrosis
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TBM100

Experimental: Tobramycin Inhalation Powder (TIP) - Eligible patients were assigned to four capsules of TIP at 28mg dosage strength, inhaled b.i.d. in the morning and in the evening via the T-326 inhaler, for 28 days (on treatment), followed by 28 days of no study treatment (off treatment). Each treatment therefore consisted of 112mg tobramycin (4 capsules of 28mg each) with the total daily dose = 224mg tobramycin (112mg b.i.d.). These 56 days represented 1 cycle of therapy.


Treatment: Drugs: TBM100
Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Treatment Emergent Adverse Events, Serious Adverse Events (SAEs) and Deaths - Adverse events were deemed treatment-emergent if the onset date/time was on or after the date and time of first study drug. All adverse events were included after this time during both on and off-treatment periods.
Timepoint [1] 0 0
337 days
Secondary outcome [1] 0 0
Relative Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Percent Predicted - Spirometry was performed at each visit. FEV1, FVC, and FEF25-75 were recorded at all visits according to American Thoracic Society (ATS) guidelines. FEV1 = the volume of air expired in 1 second. FEV1 % predicted is a normalized value of FEV1 calculated using the Knudsen equation, based upon participant's age, gender and height. FVC (forced vital capacity) = the maximal volume of air exhaled with maximally forced effort from a position of maximal inspiration. FEF25-75 = forced expiratory flow from 25% to 75% of the FVC. Relative change in FEV1 % predicted from baseline to pre-dose day X = ((pre-dose day X FEV1 % predicted - baseline FEV1 % predicted) / baseline FEV1 % predicted) • 100.
Timepoint [1] 0 0
Baseline, day 29, day 85, day 141, day 197, day 253, day 309, day 337. All study visits except baseline and day 337 occurred at the end of a 28-day on-treatment period of a cycle. Day 337 was the end of the final 28-day off treatment period.
Secondary outcome [2] 0 0
Relative Change From Baseline in FVC Percent Predicted - Spirometry was performed at each visit. FEV1, FVC, and FEF25-75 were recorded at all visits according to American Thoracic Society (ATS) guidelines. FEV1 = the volume of air expired in 1 second. FEV1 % predicted is a normalized value of FEV1 calculated using the Knudsen equation, based upon participant's age, gender and height. FVC (forced vital capacity) = the maximal volume of air exhaled with maximally forced effort from a position of maximal inspiration. FEF25-75 = forced expiratory flow from 25% to 75% of the FVC. Relative change in FVC % predicted from baseline to pre-dose day X = ((pre-dose day X FVC % predicted - baseline FVC % predicted) / baseline FVC % predicted) • 100.
Timepoint [2] 0 0
Baseline, day 29, day 85, day 141, day 197, day 253, day 309, day 337. All study visits except baseline and day 337 occurred at the end of a 28-day on-treatment period of a cycle. Day 337 was the end of the final 28-day off treatment period.
Secondary outcome [3] 0 0
Relative Change From Baseline in FEF Rate Over 25 to 75 Percent of Vital Capacity Predicted - Spirometry was performed at each visit. FEV1, FVC, and FEF25-75 were recored at all visits according to American Thoracic Society (ATS) guidelines. FEV1 = the volume of air expired in 1 second. FEV1 % predicted is a normalized value of FEV1 calculated using the Knudsen equation, based upon participant's age, gender and height. FVC (forced vital capacity) = the maximal volume of air exhaled with maximally forced effort from a position of maximal inspiration. FEF25-75 = forced expiratory flow from 25% to 75% of the FVC. Relative change in FEEF25-75 from baseline to pre-dose day X = ((pre-dose day X FEF25-75 - baseline FEF25-75) / baseline FEF25-75) • 100.
Timepoint [3] 0 0
Baseline, day 29, day 85, day 141, day 197, day 253, day 309, day 337. All study visits except baseline and day 337 occurred at the end of a 28-day on-treatment period of a cycle. Day 337 was the end of the final 28-day off treatment period.
Secondary outcome [4] 0 0
Change From Baseline in Pseudomonas Aeruginosa Colony Forming Units in Sputum - Sputum was collected in sterile containers and cultured for Pseudomonas aeruginosa (Pa.) (quantitative test) and other typical Cystic Fibrosis respiratory pathogens. The Pa. biotypes measured were mucoid, dry and small colony variant. Results are presented for the sum of all biotypes of Pa, with data transformed using a base 10 logarithm.
Timepoint [4] 0 0
Baseline, day 1, day 29, day 85, day 141, day 197, day 253, day 309, day 337
Secondary outcome [5] 0 0
Tobramycin MIC 50 and MIC 90 Values Over All Isolates for the Sum of All Biotypes (Mucoid, Dry and Small Colony Variant) of Pseudomonas Aeruginosa - Tobramycin MIC 50 and MIC 90 values were defined as the lowest concentration of tobramycin required to inhibit 50% and 90%, respectively, of the P. aeruginosa strains tested.
Timepoint [5] 0 0
Baseline, day 29, day 85, day 141, day 197, day 253, day 309, day 337
Secondary outcome [6] 0 0
Percentage of Participants Hospitalized Due to Serious Respiratory-related Adverse Events
Timepoint [6] 0 0
Day 337
Secondary outcome [7] 0 0
Number of Hospitalization Days Due to Serious Respiratory-related Adverse Events - The total number of hospitalization days due to serious respiratory-related adverse events was analyzed.
Timepoint [7] 0 0
Day 337
Secondary outcome [8] 0 0
Time to First Hospitalization Due to Serious Respiratory-related Adverse Events - The day of first hospitalization due to serious respiratory-related adverse events was analyzed.
Timepoint [8] 0 0
Day 337
Secondary outcome [9] 0 0
Percentage of Participants Who Used New Anti-pseudomonal Antibiotics
Timepoint [9] 0 0
Day 337
Secondary outcome [10] 0 0
Number of Days of New Anti-pseudomonal Antibiotic Use - The total number of days of new anti-pseudomonal antibiotic use was analyzed.
Timepoint [10] 0 0
Day 337
Secondary outcome [11] 0 0
Time to Use of New Anti-pseudomonal Antibiotic - Time to first use of new anti-pseudomonal antibiotic was analyzed.
Timepoint [11] 0 0
Day 337

Eligibility
Key inclusion criteria
- Confirmed diagnosis of Cystic Fibrosis

- FEV1 at screening must be between 25 and 75 percent of normal predicted values for
age, sex and height based on the Knudson equation

- Pseudomonas aeruginosa must be present in a sputum / deep cough throat swab culture or
bronchoalveolar lavage within 6 months prior to screening and in the
sputum/deep-throat cough swab culture at screening
Minimum age
6 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History of sputum culture or deep cough throat swab culture yielding Burkholderia
cenocepacia complex within 2 years prior to screening and /or sputum culture yielding
Burkholderia cenocepacia at screening

- Hemoptysis more than 60mL at any time within 30 days prior to study drug
administration

- History of hearing loss or chronic tinnitus deemed clinically significant

- Serum creatinine 2mg/dl or more, BUN 40mg/dl or more, or an abnormal urinalysis
defined as 2+ or greater proteinuria at screening

- Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics

- Patients who are regularly receiving more than 1 class of inhaled anti-pseudomonal
antibiotic

- Any use of inhaled or systemic anti-pseudomonal antibiotic within 28 days prior to
study drug administration

- Use of loop diuretics within 7 days prior to study drug administration

Other protocol-defined inclusion/exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - New Lambton Heights
Recruitment hospital [2] 0 0
Novartis Investigative Site - Clayton
Recruitment hospital [3] 0 0
Novartis Investigative Site - Parkville
Recruitment postcode(s) [1] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Missouri
Country [6] 0 0
United States of America
State/province [6] 0 0
Nebraska
Country [7] 0 0
United States of America
State/province [7] 0 0
Nevada
Country [8] 0 0
United States of America
State/province [8] 0 0
New Jersey
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Oklahoma
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Cordoba
Country [17] 0 0
Argentina
State/province [17] 0 0
Entre Rios
Country [18] 0 0
Canada
State/province [18] 0 0
Alberta
Country [19] 0 0
Canada
State/province [19] 0 0
Quebec
Country [20] 0 0
France
State/province [20] 0 0
Giens Cedex
Country [21] 0 0
France
State/province [21] 0 0
Montpellier
Country [22] 0 0
France
State/province [22] 0 0
Paris
Country [23] 0 0
France
State/province [23] 0 0
Reims
Country [24] 0 0
France
State/province [24] 0 0
Roscoff
Country [25] 0 0
Germany
State/province [25] 0 0
Essen
Country [26] 0 0
Germany
State/province [26] 0 0
Frankfurt
Country [27] 0 0
Hungary
State/province [27] 0 0
Budapest
Country [28] 0 0
Italy
State/province [28] 0 0
FI
Country [29] 0 0
Italy
State/province [29] 0 0
GE
Country [30] 0 0
Italy
State/province [30] 0 0
ME
Country [31] 0 0
Italy
State/province [31] 0 0
VR
Country [32] 0 0
Italy
State/province [32] 0 0
Napoli
Country [33] 0 0
Italy
State/province [33] 0 0
Palermo
Country [34] 0 0
Italy
State/province [34] 0 0
Roma
Country [35] 0 0
Mexico
State/province [35] 0 0
Distrito Federal
Country [36] 0 0
Mexico
State/province [36] 0 0
Nuevo León
Country [37] 0 0
Spain
State/province [37] 0 0
Cataluña
Country [38] 0 0
Spain
State/province [38] 0 0
Comunidad Valenciana

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study assessed the long term safety data for the use of tobramycin inhalation powder in
patients suffering from cystic fibrosis who have a chronic pulmonary infection with
Pseudomonas aeruginosa.
Trial website
https://clinicaltrials.gov/show/NCT01519661
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications